With a new cosmetic dermal filler that works twice as long as AbbVie’s Botox, Nashville, Tennessee, company Revance thought it could capture what it termed the “prestige market.” That, of course, came ...
Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC). Under the terms of the agreement, Crown will commence ...
– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. – Q4 DAXXIFY volume up 22% ...
After debuting in the aesthetics market with Daxxify last year, Revance has made its way to the potentially lucrative therapeutic space. With a Monday FDA nod to treat cervical dystonia in adults, ...
(RTTNews) - Revance Therapeutics, Inc. (RVNC) disclosed on Monday that it has entered into a merger agreement with Crown Laboratories, Inc., which plans to purchase all outstanding shares of Revance's ...
Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery
- Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more - This manuscript presents the findings from SAKURA 1 and 2 side-by-side, ...
NASHVILLE, Tenn., March 25, 2026 /PRNewswire/ -- Revance, a fast-growing global aesthetics, regenerative and consumer skincare company, will showcase the latest innovations and new indications across ...
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ...
Shares of Revance Therapeutics surged 18% Thursday after the company announced the Food and Drug Administration had approved Daxxify, a facial injection drug that Revance hopes will challenge Botox’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results